1 / 5

Retroviral Life Cycle: Latent vs. Active infection

In latent infection- retroviral genome is present but is not transcribing viral genome or mRNA for structural proteins. Distinguished by qPCR (DNA) and qRT-PCR (RNA). Retroviral Life Cycle: Latent vs. Active infection .

deon
Download Presentation

Retroviral Life Cycle: Latent vs. Active infection

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. In latent infection- retroviral genome is present but is not transcribing viral genome or mRNA for structural proteins. Distinguished by qPCR (DNA) and qRT-PCR (RNA) Retroviral Life Cycle:Latent vs. Active infection In latent infection- retroviral genome is present but is not transcribing viral genome or mRNA for structural proteins. Distinguished by qPCR (DNA) and qRT-PCR (RNA)

  2. Not a mouse contaminant XMRV is a new human retrovirus Not prostate cancer XMRV Phylogenetic analysis revealed that XMRV isolates from prostate cancer and CFS form a distinct branch within non ecotronic MLVs • Not a mouse contaminant • XMRV is a new human retrovirus • Not prostate cancer XMRV

  3. University Of Nevada, Reno Cleveland Clinic – Bob Silverman and Javdip Das Gupta Vincent Lombardi Judy Mikovits DanielPeterson Kathryn Hagen Max Pfost National Cancer Institute Sandra Ruscetti Frank Ruscetti Rachel Bagni Cari Petrow-Sadowski Bert Gold Michael Dean Detection of Infectious Xenotropic MuLV-Related Virus (XMRV)in Blood Cells From Patients With Chronic Fatigue Syndrome University of Nevada, Reno Vincent Lombardi Judy Mikovits DanielPeterson Kathryn Hagen Max Pfost Sandra Ruscetti Frank Ruscetti Rachel Bagni Cari Petrow-Sadowski Bert Gold Michael Dean Bob Silverman Jaydip Das Gupta

  4. CFS Study Cohort Reported in Science: Study cohort from the WPI national repository. Repository samples include samples from NV, CA, OR, FL, NC and NY as well as international CFS patients. Repository inclusion criteria: CFS diagnosis, regardless of severity 19-75 years of age Study characteristic: 67% women, reflecting gender incidence of CFS Mean age: 55 320 control samples from same geographic locations

  5. Questions What cell types are infected? How is XMRV transmitted? Do infected individuals make an immune response? What are the interactions between XMRV and the innate immune system? Does XMRV infection alter the risk of cancer development in CFS? Can we develop immune based therapies for CFS based on XMRV?

More Related